Polyphenols and Metabolic Health: What Meta-Analyses from 2024–2025 Show

What are polyphenols and why are they studied?

Polyphenols are a large group of plant compounds sharing a common structural characteristic: multiple hydroxyl groups attached to an aromatic ring. This group includes flavonoids (flavonols, anthocyanins, flavanones), stilbenes (resveratrol), and phenolic acids (chlorogenic acid). Different subclasses have different mechanisms of action and bioavailability.

Interest in polyphenols grew after epidemiological observations: populations with high consumption of fruits, berries, and vegetables show lower rates of cardiovascular disease and type 2 diabetes. The question is whether polyphenols are the cause of these associations or merely a marker of a healthy diet overall. Randomized trials allow us to partially separate these hypotheses.

What did the anthocyanin meta-analysis show (29 RCTs, 2025)?

Pan and colleagues (PLOS ONE, February 2025) conducted a systematic review and meta-analysis of randomized trials on anthocyanins — the pigments that give berries and red grapes their color — and metabolic syndrome risk factors. The analysis included 29 RCTs with 2,006 participants.

Key results were statistically significant and reproducible:

• LDL cholesterol decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08; p<0.001)
• Total cholesterol decreased by 0.34 mmol/L (95% CI: -0.49 to -0.18; p<0.001)
• Triglycerides decreased by 0.11 mmol/L (p=0.021)
• HDL cholesterol increased by 0.05 mmol/L (p=0.026)
• Fasting glucose decreased by 0.29 mmol/L (p=0.001)
• HbA1c decreased by 0.43% (p=0.005)

No significant effects on blood pressure, BMI, or waist circumference were found. This is an important clarification: anthocyanins affect lipid and glycemic profiles but are not a weight-loss tool on their own.

Quercetin: effects on glucose and blood pressure

Quercetin — a flavonol found in onions, apples, capers, and green tea — is one of the most studied individual polyphenols. Noshadi and colleagues (Journal of Functional Foods, 2024) conducted a dose-response meta-analysis of 20 RCTs with 1,164 participants, focusing on components of metabolic syndrome.

Results showed moderate but significant effects:

• Fasting glucose: WMD = -1.03 mg/dL (95% CI: -1.87 to -0.19)
• Systolic blood pressure: WMD = -1.96 mmHg (95% CI: -3.11 to -0.81)
• Dose threshold for the hypotensive effect: ≥500 mg/day

No significant effects on triglycerides, HDL, waist circumference, or diastolic pressure were found. The authors note that dietary quercetin intake (a typical diet provides 10–100 mg/day) is substantially lower than doses used in trials (200–1,000 mg/day). This creates a gap between dietary and supplemental dosing.

Polyphenols and the gut microbiome: data in overweight individuals

Gonzalez-Gomez and colleagues (Nutrients, 2025) analyzed 13 RCTs (670 participants with BMI ≥25) examining the effects of polyphenol-rich interventions on the gut microbiome and inflammatory markers. This is the first large meta-analysis focused specifically on the overweight population — the group with the greatest clinical interest in metabolic effects.

Key findings relate to the intestinal barrier and fermentation:

• Butyrate increased: SMD = 0.57 (95% CI: 0.18 to 0.96; p<0.001) — butyrate is the primary energy source for colonocytes and a marker of gut barrier health
• Acetate increased: SMD = 0.42 (95% CI: 0.09 to 0.75; p<0.01)
• Circulating LPS (lipopolysaccharide, a marker of gut permeability) decreased: SMD = -0.56 (95% CI: -1.10 to -0.02; p<0.04)
• Catalase activity (antioxidant enzyme) improved: SMD = 0.79 (95% CI: 0.30 to 1.28; p<0.001)

Pro-inflammatory cytokines (IL-6, TNF-alpha) showed heterogeneous results across trials — no consistent effect was observed. The mechanism by which polyphenols act on the microbiome is partly explained by the fact that most of them reach the large intestine unchanged and are fermented there by the gut flora.

Resveratrol and vascular health: nuances of bioavailability

Godos and colleagues (Frontiers in Pharmacology, 2024) synthesized data from clinical trials on resveratrol and vascular outcomes. Their review included trials with different doses, formulations, and populations. Some trials recorded reductions in systolic blood pressure of 8–10 mmHg and a 23% improvement in endothelium-dependent vasodilation from baseline. However, the authors emphasize a critical nuance: high-dose tablets (>500 mg/day) often showed null results, while low-dose dietary sources showed positive ones. The bioavailability of resveratrol is highly variable; the gut microbiota participates in its metabolism, producing active metabolites — urolithins and other compounds. This explains why the same nominal "resveratrol" in different forms can behave differently.